Welcome back to the journal review. This is our October twenty twenty-six episode, and we're working through three pieces from the Journal of the American Academy of Dermatology — a surgical pearl on managing hand edema after dermatologic surgery, and then a two-part continuing medical education series on dermatologic manifestations in patients with kidney disease. Let's get into it.

First up is a surgical pearl — a short, practical clinical-solution piece rather than a study, so we'll treat it exactly as what it is: a technique tip with a rationale and a how-to. The authors are addressing postoperative hand edema after dermatologic surgery. You know this problem well — the hand has unforgiving, confined fascial compartments, critical neurovascular bundles sitting close to the surface, and even modest swelling can crank up tension on a closure, threaten a flap or graft, raise infection risk, and stiffen the digits. The usual toolkit — ice, elevation, range-of-motion exercises, compression wraps — each has real limitations in the immediate postoperative period, particularly over a fresh dressing on a hand that the patient still needs to use.

Their solution, borrowed from the orthopedic literature, is the postoperative compression glove. The idea is straightforward physiology — graded external compression in the twenty-to-thirty millimeters of mercury range limits interstitial fluid accumulation and supports lymphatic return, while still letting the patient move the hand. The authors point to randomized data in distal radius fracture repair showing that compression gloves reduced edema, reduced pain, and improved functional outcomes compared with standard care — and their pitch here is simply that this evidence hasn't made its way into dermatologic surgery despite how directly it should translate.

The practical recipe is very specific, which is what makes this pearl immediately usable. Have the patient bring a wrist-length glove with open fingertips to their procedure, apply it right over the standard postoperative dressing, and have them wear it continuously for about a week. These gloves are inexpensive, widely available at pharmacies or online, and some versions can be frozen beforehand, which gives you simultaneous compression and cold therapy in one device. The authors are careful to flag the failure mode — fit matters, because a glove that's too tight becomes a tourniquet rather than a therapeutic compression garment. Patients need clear instructions to remove it and call if they notice numbness, worsening pain, or paradoxically worsening swelling, and you should examine the digits for ischemic change before they leave. Contraindications are the ones you'd expect — peripheral arterial occlusive disease, significant neuropathy, and active infection, where masking an evolving problem under a glove is the last thing you want.

There's no outcomes data generated by these authors themselves — this is a pearl, not a trial — so the practical takeaway is modest but genuinely actionable: for hand cases with meaningful tissue trauma or flap and graft reconstruction, this is a close-to-zero-cost, low-complexity addition you could start using this week, provided you screen for the vascular and neuropathic contraindications first.

Now to the meatier material — a two-part continuing medical education series from Weill Cornell, Yale, Duke, Brown, and Miami authors on dermatologic manifestations in kidney disease. This is a review, so there's no methods-and-results arc to walk through — instead we're synthesizing the state of the evidence disease by disease, and I'll flag where real trial data exists versus where we're in case-report or expert-opinion territory.

Part one covers manifestations of chronic kidney disease itself. The framing numbers are worth having on hand for patient conversations — chronic kidney disease affects roughly one in ten people worldwide, and about one in seven adults in the United States, and the authors cite a striking epidemiologic point that Black patients have roughly a five-fold higher risk of progressing to end-stage kidney disease compared with White patients — a disparity that's both statistically robust and clinically enormous, not a statistical footnote.

The excerpt we have focuses in depth on two conditions: chronic kidney disease-associated pruritus, and uremic xerosis — though the full review, per its stated scope, also covers pigmentary change, uremic frost, porphyria cutanea tarda, acquired perforating dermatoses, and hair and nail changes, which aren't detailed in what's in front of us today.

On chronic kidney disease-associated pruritus — formerly called uremic pruritus — this is common, underdiagnosed, and underappreciated in its downstream impact: it's tied to disrupted sleep, depression, higher infection and hospitalization risk, and even higher mortality. Reported prevalence swings widely, from under a fifth up to about half of nondialyzed patients, and over half of dialyzed patients, which the authors attribute to inconsistent diagnostic criteria rather than true biologic variability. In a decent-sized survey of itch patients, nearly a third had severe symptoms, and severity tracked with meaningfully worse quality of life. The proposed biology is multifactorial — uremic toxin deposition in skin, central and peripheral neuropathic mechanisms, an imbalance between mu and kappa opioid receptor signaling, and type-two immune dysregulation with elevated interleukin-31. There are no primary skin lesions here — what you see is secondary, excoriations, erosions, and prurigo nodules from scratching, so the workup has to rule out the usual mimics: hepatobiliary disease, hematologic disorders, diabetes, polypharmacy.

This is a good spot to build out a statistics concept, because the epidemiology section leans on odds ratios and relative risk, and it's worth being precise about what those numbers are actually telling you. An odds ratio compares the odds of an exposure in people who have the outcome versus those who don't — it's the standard output of a logistic regression model, which is the workhorse technique whenever your outcome is binary, like "developed calciphylaxis" or "didn't," and you want to adjust for multiple risk factors simultaneously rather than looking at each one in isolation. A relative risk, by contrast, directly compares incidence rates between two groups and is more intuitive but requires prospective, cohort-style data rather than a case-control design. The age effect reported here — roughly a four percent increase in odds per decade of age — is a textbook example of a statistically significant finding that is clinically almost irrelevant on its own; age by itself isn't going to change how you counsel a patient, it only matters layered alongside the stronger risk factors like advanced CKD stage or comorbid depression.

Management follows a sensible stepwise logic: optimize dialysis first — longer or more frequent sessions, or a trial of peritoneal dialysis — treat hyperphosphatemia with phosphate binders where relevant, and use topical emollients as baseline care for everyone, especially mild or localized itch. For moderate-to-severe or refractory disease, the real practice-changing development is in the kappa opioid receptor agonists. Difelikefalin, an intravenous agent, was tested in a phase three placebo-controlled trial of patients on hemodialysis and nearly doubled the proportion of patients achieving meaningful itch relief compared with placebo — a clear and statistically significant effect, with diarrhea as the most common adverse event. It was FDA-approved in twenty twenty-one and is now considered first-line for moderate-to-severe disease. Nalfurafine, the oral equivalent, showed a similar significant benefit in a Japanese phase three trial but remains approved only in Japan. Gabapentinoids have solid supporting evidence and sit as a reasonable second-line option after the opioid-receptor agents. Beyond that, the evidence gets thinner — dupilumab has case-report-level support only, aprepitant showed a modest effect in a small prospective study, and despite a biologically plausible rationale around interleukin-31, nemolizumab actually failed to show efficacy for this indication in a Japanese phase two trial, which is a useful reminder that a compelling mechanistic story doesn't guarantee clinical translation.

The second condition detailed here is uremic xerosis, affecting roughly half to three-quarters of CKD patients, thought to relate to reduced stratum corneum water content and a possible defect in aquaporin-3 channels that transport glycerol — interestingly, in the one study that looked, xerosis severity didn't correlate with itch severity, suggesting these are at least partly separate processes rather than one driving the other. Clinically it's more generalized than garden-variety xerosis and can be severe enough to fissure, bleed, and secondarily infect. The actionable data point here is a phase three randomized trial in patients with moderate-to-severe uremic xerosis showing a glycerol-and-paraffin emulsion, marketed as Dexeryl, produced significantly more symptom improvement than emulsion alone — about sixty percent versus forty percent of patients responding over four weeks, a difference that's both statistically and clinically meaningful. Heparinoid topicals are used for this indication in Japan but aren't available in the States, so for your patients the practical recommendation is a glycerol-paraffin emollient plus counseling on avoiding irritants, harsh temperature, low humidity, and excessive hand-washing.

Now to part two of the series, which shifts focus from the kidney disease itself to the skin findings that come from treating it — dialysis and its downstream effects. The framing stat here is that roughly three hundred sixty people start end-stage kidney disease treatment every day in the United States, and the authors' point is that many of these iatrogenic dermatoses are easy to misdiagnose because they mimic more common conditions.

The condition most relevant to our specialty is calciphylaxis, a potentially fatal variant of calcinosis cutis that's far more common in dialyzed patients, caused by microvascular calcification leading to thrombosis. It presents as tender, retiform purpura or firm purpuric plaques that can progress to hemorrhagic bullae, ulceration, and a black eschar, often on the legs or areas of high adiposity. The epidemiology is sobering — incidence is about thirty-five cases per ten-thousand patients in the US, and mortality is substantial: roughly a quarter of patients die within six months and nearly half within a year, with worse outcomes in those with ulcerated lesions. A large US Renal Data System study found mortality rates two-and-a-half to three times higher in calciphylaxis patients compared with hemodialysis patients overall. A case-control study identified the risk factors you'd expect from the underlying biology — diabetes roughly doubled the odds, each five-unit rise in body mass index increased odds by about a third, warfarin use roughly tripled the odds, and supplemental vitamin D roughly doubled it. One diagnostic pearl worth remembering — in over half of biopsied calciphylaxis cases, histopathology doesn't show the classic findings, so clinical and pathologic correlation has to drive the diagnosis rather than waiting for a definitive biopsy result.

This is a good place to build out another statistics concept, because the management data here leans heavily on hazard ratios from survival analyses, and it's worth understanding what that technique is actually doing differently from a simple odds ratio. A hazard ratio comes out of a Cox proportional hazards model, which is the standard tool whenever your outcome is time-to-event — death, recurrence, whatever endpoint — and patients are followed for different lengths of time, some reaching the event and some being lost to follow-up or still alive at study's end, a situation called censoring. Rather than just asking whether an event happened, the Cox model compares the instantaneous risk of that event between groups at every moment someone remains at risk, which is why it can use partial, uneven follow-up data that a simple proportion comparison would throw away or handle poorly. Two numbers from this calciphylaxis literature illustrate why the technique matters here. First, a randomized trial of the calcimimetic cinacalcet in over thirty-eight hundred dialysis patients found roughly a two-thirds reduction in the hazard of developing calciphylaxis compared with placebo — a substantial and statistically significant benefit, which is why calcimimetics are now preferred over surgical parathyroidectomy for managing the underlying metabolic derangement. Second, and somewhat counterintuitively, a retrospective cohort found that increasing hemodialysis frequency was associated with roughly a three-fold higher hazard of death in calciphylaxis patients — which argues against reflexively intensifying dialysis as a treatment strategy once someone has developed the disease. Other management threads include intravenous sodium thiosulfate used off-label during dialysis sessions, with one retrospective cohort suggesting that adding hyperbaric oxygen therapy on top of sodium thiosulfate significantly improved survival and wound healing compared with sodium thiosulfate alone. Surgical debridement is controversial given that calciphylaxis lesions can be triggered by trauma and koebnerization, so it's reserved for case-by-case conservative removal of frankly necrotic tissue, and pain control typically requires a multimodal, high-dose approach with pain-management consultation.

The other condition detailed in the excerpt is dialysis-related amyloidosis, driven by accumulation of beta-2-microglobulin amyloid fibrils that dialysis membranes clear poorly — intermediate-sized beta-2-microglobulin species can actually increase several-fold in concentration across a single dialysis session, reflecting how inadequate clearance really is. This is predominantly a disease of long-term dialysis — one autopsy series found essentially universal involvement by thirteen years on hemodialysis, with prevalence climbing steadily from about a fifth of patients at two years. Risk climbs with longer dialysis duration, older age at dialysis initiation, worse residual kidney function, and use of older low-flux rather than high-flux membranes. Cutaneously it shows up as amyloidomas — firm pink-brown subcutaneous masses that preferentially affect the buttocks and hip region, likely because these are areas of chronic mechanical loading that promote amyloid deposition. The clinical importance for us is recognizing these as a mass that can mimic other subcutaneous processes, warranting imaging and histopathologic confirmation rather than assuming a benign lipoma, and the authors note that patients found to have these amyloidomas should be screened for associated carpal tunnel syndrome and amyloid arthropathy, since the disease frequently involves osteoarticular structures more than skin. The excerpt's discussion of definitive medical management — largely centered on optimizing dialysis membrane flow characteristics — runs beyond what we have in front of us today, so we'll leave that thread for when the fuller text is available.

So, stepping back across this series: the practice-changing elements for a Mohs surgeon and dermatologic oncologist are really about pattern recognition and perioperative judgment rather than any technique you'd perform yourself. Calciphylaxis needs to be on your differential whenever a dialysis patient presents with painful retiform purpura or a nonhealing ulcer, particularly before you biopsy or debride reflexively, given how often histopathology comes back unhelpful and how high the mortality is once the diagnosis is missed or delayed. Dialysis-related amyloidomas are worth keeping in mind as a benign-appearing subcutaneous mass mimic in your long-term dialysis patients. And on the pruritus side, knowing that difelikefalin exists and is now first-line for moderate-to-severe disease is useful collaborative knowledge even though you won't be the one prescribing it — it changes what you can meaningfully suggest to a nephrology colleague. The compression glove pearl, by contrast, is the one piece of actionable, implement-tomorrow technique from this episode — cheap, low-risk, and worth adding to your postoperative hand protocol.

That's the October roundup. Thanks for listening, and we'll be back next month with another set of papers.